Logo for BenevolentAI société anonyme

BenevolentAI société anonyme Investor Relations Material

Latest events

Logo for BenevolentAI société anonyme

H1 2024

BenevolentAI société anonyme
Logo for BenevolentAI société anonyme

H1 2024

19 Sep, 2024
Logo for BenevolentAI société anonyme

H2 2023

14 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from BenevolentAI société anonyme

Access all reports
BenevolentAI société anonyme is active in the pharmaceutical industry, specializing in AI-enabled drug discovery. The company's core mission revolves around integrating artificial intelligence (AI) with advanced scientific research to innovate and develop new medications for complex diseases. It leverages its proprietary Benevolent Platform, an AI-driven drug discovery engine that utilizes a vast biomedical data landscape to offer a comprehensive representation of human biology across various diseases. This platform aids both in-house scientists and biopharmaceutical partners in accelerating scientific breakthroughs by harnessing the full potential of data and AI for the next generation of medical advancements. The company is headquartered in Luxembourg and its shares are listed on the Euronext Amsterdam stock exchange.